Global market access · Pricing · Payer strategy
Senior-level advisory for pharma and biotech teams, and the consulting firms that support them, from pre-launch pricing to HTA submissions and payer negotiation.
Who we work with
Whether you own the asset or advise the company that does, you get the same senior attention. No hand-off to junior teams.
Pharma & biotech
For global and regional market access, pricing and commercial teams who need a clear path from Phase II data to reimbursed patients.
Consulting & agency partners
For strategy consultancies, HEOR and market access agencies that want an experienced industry voice on a project team.
Services
Engagements are scoped to the decision in front of you, from a two-week pricing sprint to end-to-end launch support across markets.
Access plans that align clinical development, evidence generation and launch priorities with what payers and HTA bodies will reward.
Target price corridors, international reference pricing analysis, launch sequencing and price potential testing with payers.
Strategy for AMNOG, HAS, NICE, AIFA and the EU Joint Clinical Assessment, including comparator choice and PICO scenario planning.
A clear, evidence-backed value narrative and objection handler that local affiliates can use in negotiations.
Outcomes-based agreements, managed entry agreements and other risk-sharing structures, designed to be workable for both sides.
Real-world evidence plans that answer payer questions, plus AI-assisted predictive models for pricing and access outcomes.
Markets
Particular depth in the markets that set reference prices and shape global launch decisions.
| Region | Markets | Key decision bodies |
|---|---|---|
| United States | Commercial, Medicare, Medicaid | CMS IRA negotiation PBMs ICER |
| Europe (EU5 + EU) | Germany, France, Italy, Spain, UK | G-BA/IQWiG HAS/CEPS AIFA CIPM NICE EU JCA |
| Asia | Japan, China | PMDA Chuikyo NHSA NRDL |
| Latin America | Brazil | ANVISA CMED CONITEC |
| Middle East | Saudi Arabia, UAE and the Gulf | SFDA NUPCO DoH Abu Dhabi |
Therapeutic areas with positive HTA and payer outcomes
How an engagement runs
Every project follows the same four stages, sized to your timeline and budget.
Review the asset, evidence and competitive landscape. Agree the decision to be made and the markets that matter.
Pressure-test value and price assumptions through payer research, advisory boards and HTA precedent.
Pricing corridors, launch sequence, evidence plan and value story, with the trade-offs made explicit.
Hand-over materials, affiliate workshops and ongoing support through submissions and negotiations.
About the founder
Founder & Principal, AC Strategic Solutions
Ario has spent more than 18 years securing access and commercial success for innovative therapies. He has built payer value stories, led pricing strategy and secured positive HTA and payer appraisals for assets in oncology, rare diseases, neuroscience, immunology and virology.
He founded AC Strategic Solutions to give sponsors and consulting partners direct access to that experience, in a boutique model where the person you meet is the person who does the work.